CORONA

Corona Remedies Share Price

 

 

Start SIP in CORONA

Start SIP
Corona Remedies live price: ₹1588.6. It opened at ₹1,610 vs previous close ₹1,617; intraday high/low: ₹1,622/₹1,582. The 50 DMA stands at ₹1,512.22.

Corona Remedies Performance

  • Low
  • ₹1,582
  • High
  • ₹1,622
  • 52 Week Low
  • ₹1,337
  • 52 Week High
  • ₹1,699
  • Open Price₹1,610
  • Previous Close₹1,617
  • Volume7,599
  • 50 DMA₹1,512.22
  • 100 DMA-
  • 200 DMA-

Investment Returns

  • Over 1 Month -1.13%
  • Over 3 Month + 49.59%
  • Over 6 Month + 49.59%
  • Over 1 Year + 49.59%

Smart Investing Starts Here Start SIP with Corona Remedies for Steady Growth!

Invest Now

Corona Remedies Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -
  • PEG Ratio
  • -
  • Market Cap Cr
  • 9,716
  • P/B Ratio
  • 13.9
  • Average True Range
  • 60.13
  • EPS
  • 30.17
  • Dividend Yield
  • 0
  • MACD Signal
  • 26.22
  • RSI
  • 53.41
  • MFI
  • 75.51

Corona Remedies Financials

Corona Remedies Technicals

EMA & SMA

Current Price
₹1,588.60
-27.9 (-1.73%)
pointer
  • Bearish Moving Average 3
  • Bullish Moving Average 8
  • 20 Day
  • ₹1,575.94
  • 50 Day
  • ₹1,512.22
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

1597.57 Pivot Speed
  • R3 1,652.33
  • R2 1,637.07
  • R1 1,612.83
  • S1 1,573.33
  • S2 1,558.07
  • S3 1,533.83

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Corona Remedies Limited is a fast-growing Indian pharmaceutical company focused on women’s healthcare, cardio-diabeto, pain management, and urology. It operates two manufacturing facilities in Gujarat and Himachal Pradesh with 11 production lines and EU-GMP/WHO-GMP certifications.

Corona Remedies Ltd has an operating revenue of Rs. 2,246.51 Cr. on a trailing 12-month basis. An annual revenue growth of 18% is outstanding, Pre-tax margin of 17% is great, ROE of 24% is exceptional. The company has a reasonable debt to equity of 3%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 7% and 8% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 82 which is a GOOD score indicating consistency in earnings, a RS Rating of 83 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 44 indicates it belongs to a fair industry group of Medical-Ethical Drugs and a Master Score of B is close to being the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Corona Remedies Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-02 Quarterly Results
2026-01-02 Quarterly Results Inter-alia, to consider and approve the financial results for the period ended September 30, 2025

Corona Remedies F&O

Corona Remedies Shareholding Pattern

69%
6.38%
0.34%
1.84%
0%
1.36%
21.08%

About Corona Remedies

  • NSE Symbol
  • CORONA
  • BSE Symbol
  • 544644
  • Managing Director & CEO
  • Mr. Niravkumar Kirtikumar Mehta
  • ISIN
  • INE02ZQ01018

Similar Stocks to Corona Remedies

Corona Remedies FAQs

Corona Remedies share price is ₹1,588 As on 13 March, 2026 | 02:06

The Market Cap of Corona Remedies is ₹9715.9 Cr As on 13 March, 2026 | 02:06

The P/E ratio of Corona Remedies is As on 13 March, 2026 | 02:06

The PB ratio of Corona Remedies is 13.9 As on 13 March, 2026 | 02:06

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23